Short answer
Bio-rad Laboratories Inc (BIO) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.05 (Costs Associated with Exit or Disposal Activities). Bio-Rad announced financial results for the quarter ended June 30, 2026.
Bio-rad Laboratories Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Bio-Rad announced financial results for the quarter ended June 30, 2026
- Supplemental Earnings Presentation referenced under Item 7.01, with detailed results in Exhibit 99.1
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Strategy-driven restructuring initiated July 31, 2026, targeting global operations and functions
- Estimated pre-tax charges of approximately $80 million to $90 million, primarily termination benefits and severance
- Workforce reductions, function consolidations, and facility closures, with international plans subject to consultations
- Substantial completion expected by fiscal year 2027, with potential for additional charges and cash payments
- Near-term earnings pressure, with anticipated cost savings and operating improvement as the strategic objective
Item 7.01 · Regulation FD Disclosure
- Supplemental earnings presentation covers Bio-Rad’s quarter ended June 30, 2026
- Materials available through Bio-Rad Investor Relations and Exhibit 99.2
- Presentation provides additional context for investors beyond the core earnings disclosure
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $651.0M, essentially flat year over year; currency-neutral revenue declined 1.9%
- Life Science revenue $252.0M, down 4.1% reported and 5.1% currency-neutral amid academic research weakness
- Clinical Diagnostics revenue $399.0M, up 2.6% reported and 0.3% currency-neutral, partially offsetting Life Science pressure
- Non-GAAP operating margin 12.5% versus 13.6%; non-GAAP EPS $2.62 versus $2.61, while GAAP EPS benefited from investment valuation gains
- Full-year outlook reaffirmed: non-GAAP currency-neutral revenue decline of approximately 3.0% to growth of 0.5%, operating margin 10.0% to 12.0%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-rad Laboratories Inc 8-K filings
Get the next BIO 8-K as it lands
Follow BIO for push alerts, or ask the research agent what this filing means.